Introducing NucleoGLIO: Pioneering Progress in Glioblastoma Research
We are excited to unveil NucleoGLIO, a groundbreaking project at the forefront of glioblastoma research, funded by the BioWin competitiveness cluster of the Walloon Region. This collaborative initiative brings together a dynamic consortium of industrial leaders, including QUALIblood and Belgian Volition, alongside esteemed academic partners from the University of Namur and UCLouvain.
NucleoGLIO centers its efforts on advancing liquid biopsy technologies and identifying biomarkers rooted in post-translational modifications of nucleosomes. By focusing on glioblastoma, the most aggressive form of brain cancer, the project aims to revolutionize diagnostic and monitoring approaches, ushering in a new era of precision medicine.
The anticipated outcomes of NucleoGLIO include the development of advanced liquid biopsy protocols tailored for glioblastoma, alongside a comprehensive catalog of nucleosome-based biomarkers. These deliverables hold immense promise for transforming clinical practices, offering more effective tools for early detection and personalized treatment strategies.
In essence, NucleoGLIO stands as a testament to the power of collaborative innovation, where industry and academia converge to address a critical healthcare challenge. This project not only pushes the boundaries of scientific discovery but also brings hope for improved outcomes in the diagnosis and management of glioblastoma.
Do you want to know more about the projet ? Listen Jonathan Decarpentrie presenting this project during the ESMO Congress 2023: https://medimix.be/onco/cell-line-study-of-nucleosome-based-biomarkers-in-the-diagnosis-and-detection-of-relapses-in-glioblastoma/
For inquiries, collaborations, or further information, please contact us.
